KO of NF2 resulted in an increased resistance to IFN-γ and has also been linked to BRAF inhibitor resistance,45,68 consistent with an overlap between ICB resistance and mitogen-activated protein kinase inhibitor resistance pathways,69 with possible implications for the efficacy of ICB in melanoma patients pre-treated with BRAF inhibitors. Here, NF2 is linked to melanoma.